Fig. 6: Assessing the safety, efficacy, and stability of DIGIT/mRNA complexes.
From: Discrete Immolative Guanidinium Transporters deliver mRNA to specific organs and red blood cells
a Redosing mice with DIGIT/mfluc formulations for 3 consecutive weeks (0.25 mg/kg) (N = 3). Data are presented as mean values +/− SD. Illustrations created in BioRender. Zhang, R. (2025) https://BioRender.com/c7fqb80. b Levels of inflammatory cytokines before and after administration of DIGIT/mRNA complexes (0.5 mg/kg) (N = 3). Data are presented as mean values +/− SD. Two-way ANOVA was applied for multiple comparisons testing. P-values = >0.9999, >0.9999, 0.6686, 0.1714, >0.9999, 0.8273. ns = not significant. c Weight change in mice after administration of DIGIT/mRNA complexes. (N = 3). Data are presented as mean values +/− SD. d H&E staining of isolated organs 1 week after administration of DIGIT/mRNA complexes (20x mag, scale 50 μm). e Luciferase protein expression of DIGIT/mRNA complexes freshly prepared (Day 0) or stored at −80 °C for given days (N = 3). Data are presented as mean values +/− SD. Source data are provided as a Source Data file.
